Breast Cancer Clinical Trial

Clinical Trial Finder Breast Cancer Trials

XELOX for Metastatic Breast Cancer

See Locations Near You

Summary

Both capecitabine and oxaliplatin have single agent activity in breast cancer. The combination has improved activity in other solid tumors. This study seeks to assess the activity of the combination in breast cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

preserved organ function
good performance status
no more than one prior therapy
no active brain metastasis

Exclusion Criteria:

No prior capecitabine or oxaliplatin
no con-current therapy

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

37

Study ID:

NCT00204776

Recruitment Status:

Completed

Sponsor:

University of Wisconsin, Madison

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Wisconsin
Madison Wisconsin, 53792, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

37

Study ID:

NCT00204776

Recruitment Status:

Completed

Sponsor:


University of Wisconsin, Madison

How clear is this clinincal trial information?

Clinical Trial Resources

SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials for Breast Cancer
Have You Been Diagnosed With Late-Stage Breast Cancer? Know That You Have Treatment Options.
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider